These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7783576)

  • 1. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?
    Hux JE; Naylor CD
    Med Decis Making; 1995; 15(2):152-7. PubMed ID: 7783576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different ways to describe the benefits of risk-reducing treatments: a randomized trial.
    Halvorsen PA; Selmer R; Kristiansen IS
    Ann Intern Med; 2007 Jun; 146(12):848-56. PubMed ID: 17577004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment decision-making and the form of risk communication: results of a factorial survey.
    Hembroff LA; Holmes-Rovner M; Wills CE
    BMC Med Inform Decis Mak; 2004 Nov; 4():20. PubMed ID: 15546488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' responses to risk information about the benefits of treating hypertension.
    Misselbrook D; Armstrong D
    Br J Gen Pract; 2001 Apr; 51(465):276-9. PubMed ID: 11458479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who decides when to start preventive treatment? A questionnaire survey to compare the views of different population subgroups.
    Lewis DK; Barton S
    J Epidemiol Community Health; 2003 Apr; 57(4):241-2. PubMed ID: 12646536
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting.
    Till LT; Voris JC; Horst JB
    J Manag Care Pharm; 2003; 9(3):269-73. PubMed ID: 14613471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative therapy use and adherence to antihyperlipidemic drugs in a lipid clinic.
    O'Donnell DC; Brown CM; Piziak VK
    Am J Health Syst Pharm; 2001 Jun; 58(11):1017-21. PubMed ID: 11402475
    [No Abstract]   [Full Text] [Related]  

  • 8. Women's willingness to accept perceived risks for vasomotor symptom relief.
    Johnson FR; Ozdemir S; Hauber B; Kauf TL
    J Womens Health (Larchmt); 2007 Sep; 16(7):1028-40. PubMed ID: 17903080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment effect expressed as the novel Delay of Event measure is associated with high willingness to initiate preventive treatment - A randomized survey experiment comparing effect measures.
    Berglund E; Westerling R; Sundström J; Lytsy P
    Patient Educ Couns; 2016 Dec; 99(12):2005-2011. PubMed ID: 27499030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General Practitioners' coronary risk estimates, decisions to start lipid-lowering treatment, gender and length of clinical experience: their interactions in primary prevention.
    Vancheri F; Strender LE; Backlund LG
    Prim Health Care Res Dev; 2013 Oct; 14(4):394-402. PubMed ID: 23351666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' preferences for ways to communicate benefits of cardiovascular medication.
    Goodyear-Smith F; Kenealy T; Wells S; Arroll B; Horsburgh M
    Ann Fam Med; 2011; 9(2):121-7. PubMed ID: 21403138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Secondary prevention of ischemic heart disease in the Cuidad Real Province, Spain. Effectiveness of lipid-lowering therapy in primary health care].
    Groupo de Investigation del estudio ELIPSE (El Estudio de Lípidos en Prevención Secundaria de Cardiopatía Isquémica)
    Med Clin (Barc); 2000 Sep; 115(9):321-5. PubMed ID: 11093891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to lipid-lowering agents among 11,042 patients in clinical practice.
    Wong MC; Jiang JY; Griffiths SM
    Int J Clin Pract; 2011 Jul; 65(7):741-8. PubMed ID: 21676117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Speaking of risk, managing uncertainty: decision-making about cholesterol-reducing treatment in general practice.
    Kirkegaard P; Risør MB; Edwards A; Junge AG; Thomsen JL
    Qual Prim Care; 2012; 20(4):245-52. PubMed ID: 23113909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to antihyperlipidemic medication and lipid control in diabetic Veterans Affairs patients with psychotic disorders.
    Nelson LA; Graham MR; Lindsey CC; Rasu RS
    Psychosomatics; 2011; 52(4):310-8. PubMed ID: 21777713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presenting risk information to people with diabetes: evaluating effects and preferences for different formats by a web-based randomised controlled trial.
    Edwards A; Thomas R; Williams R; Ellner AL; Brown P; Elwyn G
    Patient Educ Couns; 2006 Nov; 63(3):336-49. PubMed ID: 16860964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants for acceptance of preventive treatment against heart disease - a web-based population survey.
    Bo NJ; Ejg JD; Dorte GH; Lind BB; Veldt LP
    BMC Public Health; 2014 Aug; 14():783. PubMed ID: 25086654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
    Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are preventive drugs preventive enough? A study of patients' expectation of benefit from preventive drugs.
    Trewby PN; Reddy AV; Trewby CS; Ashton VJ; Brennan G; Inglis J
    Clin Med (Lond); 2002; 2(6):527-33. PubMed ID: 12528966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.